AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

RecruitingPhase 4Ages 18 Years - anyAllQinhuangdao Hospital of Traditional Chinese Medicโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a randomized, controlled clinical study conducted across multiple centers. The neurosurgical robot can be used to treat patients with acute intracerebral hemorrhage (ICH). Establish a cohort comprising 200 participants with cognitive impairment after robot-assisted neurosurgery treatment for ICH. Two hundred participants are randomly assigned to either an experimental group (n=100) or a control group (n=100). The experimental group receive conventional treatment and oral administration of Fufang Congrong Yizhi Capsules (FCYC) for 12 weeks, while the control group receive only conventional treatment. The object of the current study is 1) to observe the security and effectiveness of FCYC and 2) to decipher the contributing factors to cognitive impairment after robot-assisted neurosurgery treatment for intracerebral hemorrhage.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion criteria: 1. Meet the diagnostic criteria of intracerebral hemorrhage (ICH) and use a neurosurgical robot to treat ICH; 2. Meet diagnostic criteria for post-stroke cognitive impairment (PSCI); 3. Meet traditional Chinese medicine (TCM) diagnosis of deficiency of the liver and kidney, phlegm and stagnant blood obstructing the meridians pattern; 4. Aged 18 and above; 5. Not limit gender; 6. 2 weeks after the onset of ICH; 7. The participants are conscious, possess sufficient visual and auditory recognition, and are capable of undergoing neuropsychological evaluation; 8. Submit informed consent. Exclusion criteria : 1. Other types of dementia besides vascular dementia (VD), such as Alzheimer's disease(AD), dementia with Lewy bodies (DLB), and frontotemporal dementia; 2. Patients with other systemic diseases that can affect cognitive function, such as Parkinson's disease (PD), normal pressure hydrocephalus (iNPH), brain tumor, encephalitis, thyroid dysfunction, severe anemia, syphilis, and acquired immune deficiency syndrome(AIDS); 3. Patients are unable to participate in the examination who have severe visual or auditory impairments, apraxia, aphasia, or apparent neurological abnormalities; 4. Patients with communication difficulties, patients with mental illness; 5. Patients with depression, Hamilton Depression Scale ( HAMD ) โ‰ฅ 17 points; 6. Patients with alcohol or drug dependency diagnosed within 6 months; 7. Patients with severe liver, kidney, or heart failure or other serious primary diseases; 8. Preconceptional, lactating, and pregnant women
๐Ÿ’Š

What it tests

  • FCYC+Conventional treatment
  • conventional treatment
๐Ÿ“

Where

6 sites
Second Affiliated Hospital of Tsinghua University
Beijing, China
Qinhuangdao Hospital of Traditional Chinese Medicine
Qinhuangdao, China
Kaifeng Third People's Hospital
Kaifeng, China
Shandong Public Health Clinical Center
Jinan, China
Weifang Hospital of Traditional Chinese Medicine
Weifang, China
Kunming Sanbo Brain Hospital
Kunming, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy